CD19.CAR T细胞来源的细胞外囊泡表达CAR并杀伤白血病细胞,有助于抗肿瘤治疗
研究对22例接受CD19 CAR T细胞输注的患者监测循环CD19 CAR+ T细胞来源细胞外囊泡(CD19.CAR+EVs),并分离鉴定其杀伤功能,同时开发符合药品生产质量管理规范(GMP)的分离方法。结果显示CD19.CAR+EVs在输注后外周血中可检测长达2年,其早期浓度下降与CAR T细胞治疗失败相关,且对CD19+细胞系和原代细胞产生显著、特异、剂量依赖性细胞毒作用,GMP分离方法回收率为63%±5.7%。
要点
- 22例CD19 CAR T细胞输注患者外周血中CD19.CAR+EVs可检测长达2年。
- 循环CD19.CAR+EV浓度早期下降与CAR T细胞治疗失败相关。
- CD19.CAR+EVs对CD19+细胞系和原代细胞产生显著、特异、剂量依赖性细胞毒作用。
核心结论
- CD19.CAR+EVs可作为CAR T细胞活性的动态生物标志物,并因直接杀伤白血病靶细胞而具有治疗潜力,可独立于CAR T细胞输注。
研究设计与样本
- 对22例接受CD19 CAR T细胞输注的患者队列监测循环CD19 CAR+ T细胞来源细胞外囊泡(CD19.CAR+EVs),并分离进行功能鉴定。
- 开发了符合药品生产质量管理规范(GMP)的CD19.CAR+EVs分离方法。
主要发现
- CD19.CAR+EVs在输注后外周血中可检测长达2年,提示其亲本细胞持久存在。
- 循环CD19.CAR+EV浓度早期下降与CAR T细胞治疗失败相关。
- 循环CD19.CAR+EVs中位大小(标准差)为133.1±65.5 nm,携带促凋亡蛋白货物。
- CD19.CAR+EVs表达的CAR水平高于其亲本细胞。
- CD19.CAR+EVs不激活异体T细胞,对CD19+细胞系和原代细胞产生显著、特异、剂量依赖性细胞毒作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell-derived extracellular vesicles (EVs) might represent a new therapeutic tool for boosting CAR T-cell antileukemic effects. Here, a cohort of 22 patients who received infusion with CD19 CAR T cells were monitored for the presence of circulating CD19 CAR+ T-cell-derived EVs (CD19.CAR+EVs), which were then separated and functionally characterized for their killing abilities. A good manufacturing practice (GMP)-compliant separation method was also developed. Results demonstrated that CD19.CAR+EVs were detectable in peripheral blood up to 2 years after infusion, indicating long-lasting persistence of their parental cells. Notably, early decreases of circulating CD19.CAR+EV concentrations correlated with failure of CAR T-cell therapy. Circulating CD19.CAR+EVs displayed a median size (standard deviation) of 133.1 ± 65.5 nm and carried a proapoptotic protein cargo. These EVs expressed higher CAR levels than their parental cells. Furthermore, CD19.CAR+EVs did not activate heterologous T cells and produced significant, specific, and dose-dependent cytotoxic effects on CD19+ cell lines and primary cells. The new GMP-compliant EV isolation method allowed for a recovery of 63% ± 5.7% of CD19.CAR+EVs. A deeper analysis of the different protein cargoes carried by EVs derived from different CAR T-cell subpopulations identified a proapoptotic functional pathway linked to CD8+LAG-3+ EVs. Overall, our data indicate that CD19.CAR+EVs may be proposed as promising dynamic new biomarkers of CAR T-cell activity and, by contributing to the direct killing of leukemic targets, represent a new product with strong therapeutic potential that could be infused independently of CAR T cells.
引用
- Lanuti P, Guardalupi F, Corradi G, et al. CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy. Blood Adv. 2025. PMID: 39903124. doi:10.1182/bloodadvances.2024014860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。